Building a moat to help pharmaceutical enterprises improve their enthusiasm for innovation and competitiveness

The right of drug invention has been paid more and more attention in China In recent years, disputes caused by drug infringement have occurred from time to time While the protection has aroused people's attention, it also makes pharmaceutical enterprises realize that they should take up the legal weapons to protect their products "Intellectual property is a necessary factor," said Wang Xijuan, chairman of Kangchen pharmaceutical "Without the protection of intellectual property, the drugs we developed may be all over the street overnight." The author understands that in terms of intellectual property protection, domestic pharmaceutical enterprises have achieved fruitful results In addition, many pharmaceutical enterprises have listed it in the rules and regulations of relevant enterprises to standardize and systematize the management of intellectual property rights In the development planning of enterprises, they have formulated practical work plans and implementation plans for intellectual property rights They have also made use of the administrative protection and judicial protection channels of national intellectual property rights to ensure the quantity and quality of their own intellectual property rights Why is intellectual property so important for innovative drug companies? Some insiders pointed out that the application of measuring a pharmaceutical enterprise's R & D ability and predicting its future development direction is undoubtedly one of the more reliable and intuitive indicators Because the new drugs enter the clinic about 3-5 years after application Wang Xijuan also gave an example, "for innovative drug research and development, first of all, a large number of suitable compounds should be screened It is possible to screen out the more appropriate target from the 5000 to 10000 compounds that are considered to be valuable, and finally determine 1 to 2 compounds for drug-forming research " Such a large number of screening work is worthy of respect, so it is necessary to protect intellectual property rights at the nodes, and then carry out pre clinical pharmaceutical research, safety evaluation, clinical approval of drugs, etc "The first phase of clinical practice is completed At the beginning of the second phase of clinical practice, we will consider the overall layout, such as crystal form series, which we now call the moat." So it seems that in the process of new drug research and development, pharmaceutical companies are like seizing a city, planting a flag of their own and announcing the right of pharmaceutical companies At present, in view of the domestic market, it is reported that after 2016, China has put forward more and higher requirements for the research and development of innovative drugs, which has forced local biomedical research and development enterprises to compete with multinational companies In contrast, the products we own naturally have a higher level and more advantages to participate in the competition This urges Chinese pharmaceutical enterprises to pay attention to property right awareness and strengthen product application For the foreign market, with the development of globalization, Chinese pharmaceutical companies also try to take the international road According to the relevant data, since 2010, the number of applications for the United States in China has been growing steadily, and the number of applications even exceeds that of the United Kingdom, France and other countries, and the number of applications is still increasing in recent years It is reported that these local pharmaceutical enterprises mainly produce generic drugs, and most of them apply for generic drugs Experts say applications don't need to be completely innovative Generic drugs can also be applied for if there are non obvious conditions For example, some drugs innovate the preparations of the original drugs, and make use of inhalation dosage forms and nanotechnology to make the generic drugs more effective (compared with the original drugs), or even expand the indications In general, the awareness of property rights is worthy of every pharmaceutical person's attention With the protection of intellectual property rights, pharmaceutical enterprises can have the enthusiasm for innovation Only by building a moat can pharmaceutical enterprises further improve their competitiveness, make their products have more vitality in the market, and at the same time protect the rights and interests of patients.